Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04657224 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT04657224 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 75 participants.
The verdict
NCT04657224, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation); and the safety of the RP2Ds for this combination in different histologies/participant populations (Part B - Cohort Expansion).
Interventions
- DRUG JNJ-64264681
- DRUG JNJ-67856633
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2025-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04657224
The ClinicalTrials.gov registry entry for NCT04657224 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-64264681 is the first listed.
NCT04657224 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04657224 about?
NCT04657224 is a clinical study titled "A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia". The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Part A - Dose Escalation); and the safety of the RP2Ds f...
What is the current status of trial NCT04657224?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2021-02-25. Estimated completion is 2025-01-16.
What interventions are being tested in trial NCT04657224?
The interventions under investigation include: JNJ-64264681 (DRUG), JNJ-67856633 (DRUG).
Who is sponsoring clinical trial NCT04657224?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.